(Q49112520)

English

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

scientific article published on 3 March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

phase II clinical trial

0 references

Teofila Seremet

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Max Schreuer

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Yanina Jansen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Simon Planken

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Ines Chevolet

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

4 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

464-472

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930171-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30171-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28268064%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49112520&oldid=1743700830"